In:
Alimentary Pharmacology & Therapeutics, Wiley, Vol. 17, No. 4 ( 2003-02), p. 553-560
Abstract:
Aim : To test the efficacy of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy for the second‐line treatment of Helicobacter pylori infection. Methods : One hundred and nine patients who had failed previous H. pylori eradication were randomized to receive: (i) rabeprazole, 20 mg b.d., rifabutin, 300 mg once daily, and levofloxacin, 500 mg once daily, for 7 days (triple therapy); or (ii) rabeprazole, 20 mg b.d., metronidazole, 400 mg t.d.s., bismuth subcitrate, 120 mg q.d.s., and tetracycline, 500 mg q.d.s., for 7 days (quadruple therapy). Endoscopy and culture were performed before treatment. Results : The clarithromycin (79% vs. 21%, P 〈 0.001) and metronidazole (89% vs. 40%, P 〈 0.001) resistance rates were significantly higher in patients with previous exposure than in those with no previous exposure. The intention‐to‐treat and per protocol eradication rates were 91%/91% for the triple therapy group and 91%/92% for the quadruple therapy group. For patients with double resistance to metronidazole and clarithromycin, the eradication rates were 85% (17/20) in the triple therapy group and 87% (13/15) in the quadruple therapy group. Compliance was greater than 95% for both regimens. Conclusion : Rabeprazole, levofloxacin and rifabutin‐based triple therapy and quadruple therapy were equally effective as second‐line treatments for H. pylori infection.
Type of Medium:
Online Resource
ISSN:
0269-2813
,
1365-2036
DOI:
10.1046/j.1365-2036.2003.01459.x
Language:
English
Publisher:
Wiley
Publication Date:
2003
detail.hit.zdb_id:
639012-2
detail.hit.zdb_id:
2003094-0
SSG:
15,3
Permalink